This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Guangzhou Xiangxue Pharmaceutical Co., Ltd., Hangzhou Converd Co., Ltd.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Innovations by Shuiping Shi
Introduction
Shuiping Shi is an accomplished inventor based in Hangzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug formulations. With a total of 2 patents, his work focuses on improving the solubility and bioavailability of poorly soluble drugs.
Latest Patents
Shuiping Shi's latest patents include a pharmaceutical composition that features an active component KX2-361 and hydroxylpropoxyl-β-cyclodextrin. This innovative drug inclusion complex enhances the solubility of KX2-361, making it suitable for both intravenous and oral preparations. His second patent involves an oral preparation for treating cell proliferation diseases, which also utilizes hydroxylpropoxyl-β-cyclodextrin to improve the solubility and stability of KX2-361. These formulations demonstrate high safety, good absorbability, and economical cost, making them valuable in medical applications.
Career Highlights
Throughout his career, Shuiping Shi has worked with notable companies such as Guangzhou Xiangxue Pharmaceutical Co., Ltd. and Hangzhou Converd Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Shuiping Shi has collaborated with professionals like Qingyong Zhang and Ronghua Zhao, further enhancing his research and development efforts in the pharmaceutical industry.
Conclusion
Shuiping Shi's contributions to pharmaceutical innovations, particularly in drug solubility and formulation, highlight his role as a significant inventor in the field. His patents reflect a commitment to improving drug delivery systems and patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile